C
China SXT Pharmaceuticals Inc.
Biotechnology: Pharmaceutical Preparations company
Key Metrics of China SXT Pharmaceuticals Inc.
Revenue$1.9M▼ 2.2% YoYFY 2023
Operating income−$2.5M▲ 55.1% YoY
Net profit−$3.1M▲ 47.8% YoY
Shareholders' equity—
Market cap$497KSXTC · $0.05
Competitors10identified
About China SXT Pharmaceuticals Inc.
Sectors
Company details
- Founded
- 2019
- Listed
- Nasdaq: SXTC (since 2019)
Operational Areas of China SXT Pharmaceuticals Inc.
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameChina SXT Pharmaceuticals Inc.
TickerSXTC
ExchangeNasdaq
CountryChina
SEC CIK0001723980
Listed since2019
IndustryBiotechnology: Pharmaceutical Preparations
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
SXTC · Nasdaq · SEC CIK 0001723980
Last price · 23 Oct 2026
$0.05
−34.25%
Market cap$497K
P/E—On FY 2023 diluted EPS
Volume57,488,709
SectorHealth CareBiotechnology: Pharmaceutical Preparations
Country · IPOChinaListed 2019
SXTC share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of China SXT Pharmaceuticals Inc.
Competitors10identified
Countries2most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | gsk.com | 2022 | United Kingdom | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States | |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States |
Similar companies
H
Hester Biosciences LimitedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
M
Medicamen Biotech LimitedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
C
Concord Biotech LimitedPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
S
SELLAS Life Sciences Group Inc.Pharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
N
Novartis AGPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
N
Neurocrine BiosciencesPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
B
BioMarin PharmaceuticalPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
B
Bio-Rad LaboratoriesPharmaceuticals & Healthcare
Same segment: Biotechnology & Vaccines
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.